Prediction of smoking relapse and difficulty during quit attempts will increase in importance as we try to match the characteristics of smokers and treatments, thereby increasing the probability of success. Methods used to assess pharmacological aspects of nicotine dependence have shown some promise as screening instruments, but little is known about nonpharmacological aspects of nicotine dependence, their interrelationships with pharmacological aspects, and the relationship of the various nicotine dependence dimensions to the course and outcome of attempts to quit smoking. Moreover, very little is known about nicotine dependence in smokers who will try to quit on their own or with minimal assistance, who represent the majority of smokers who wish to quit. This study will assess pharmacological and nonpharmacological dimensions of nicotine dependence in a sample of smokers who wish to quit on their own. Measures will include smoking motives, smoking temptations, reactivity to smoking cues, behavioral and biological parameters of nicotine intake, nicotine tolerance, and regulation of blood nicotine levels. Smokers will be assessed before they quit smoking, and they will be followed repeatedly in time for one year after attempted cessation. The measures of nicotine dependence will be used to construct and contrast several multidimensional theories on nicotine dependence. Multidimensional nicotine dependence profiles will be constructed according to the best fitting theoretical model. Smokers will be grouped according to similarity of nicotine dependence profiles, and group differences will be examined on intensity and duration of nicotine withdrawal symptoms, time until relapse and situational antecedents of relapse. The results of this study will advance our understanding of the nature of nicotine dependence and will have direct implications for future studies which utilize assessments to screen and match smokers to appropriate treatments.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL032318-06A1
Application #
3343681
Study Section
Behavioral Medicine Study Section (BEM)
Project Start
1983-09-30
Project End
1994-03-31
Budget Start
1991-04-01
Budget End
1992-03-31
Support Year
6
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Miriam Hospital
Department
Type
DUNS #
039318308
City
Providence
State
RI
Country
United States
Zip Code
02906
David, Sean P; Strong, David R; Leventhal, Adam M et al. (2013) Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction 108:2202-11
Niaura, Raymond S; Pearson, Jennifer L; Abrams, David B (2013) Compensation predicts smoking cessation failure. Psychopharmacology (Berl) 230:261-6
Leventhal, A M; David, S P; Brightman, M et al. (2012) Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Pharmacogenomics J 12:86-92
Li, Yimei; Wileyto, E Paul; Heitjan, Daniel F (2010) Modeling smoking cessation data with alternating states and a cure fraction using frailty models. Stat Med 29:627-38
Strong, David R; Kahler, Christopher W; Leventhal, Adam M et al. (2009) Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment. Nicotine Tob Res 11:1142-53
Uhl, George R; Liu, Qing-Rong; Drgon, Tomas et al. (2008) Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 65:683-93
Uhl, George R; Drgon, Tomas; Johnson, Catherine et al. (2008) Molecular genetics of addiction and related heritable phenotypes: genome-wide association approaches identify ""connectivity constellation"" and drug target genes with pleiotropic effects. Ann N Y Acad Sci 1141:318-81
David, Sean P; Brown, Richard A; Papandonatos, George D et al. (2007) Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 9:821-33
David, Sean P; Strong, David R; Munafo, Marcus R et al. (2007) Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res 9:1251-7
Brown, Richard A; Niaura, Raymond; Lloyd-Richardson, Elizabeth E et al. (2007) Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine Tob Res 9:721-30

Showing the most recent 10 out of 49 publications